GV leads $21 mln Series B for Cambridge Epigenetix
UK-based Cambridge Epigenetix (CEGX), a developer of epigenetic sequencing technologies, closed a $21 million Series B financing round led by GV with signification participation from Sequoia Capital. Current investors New Science Ventures, Syncona Partners and Cambridge University also joined the round.
14 March 2016•3 mins read
